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Abstract
Background: Loss of heterozygosity (LOH) is an important marker for one of the 'two-hits' required for tumor 
suppressor gene inactivation. Traditional methods for mapping LOH regions require the comparison of both tumor 
and patient-matched normal DNA samples. However, for many archival samples, patient-matched normal DNA is not 
available leading to the under-utilization of this important resource in LOH studies. Here we describe a new method for 
LOH analysis that relies on the genome-wide comparison of heterozygosity of single nucleotide polymorphisms (SNPs) 
between cohorts of cases and un-matched healthy control samples. Regions of LOH are defined by consistent 
decreases in heterozygosity across a genetic region in the case cohort compared to the control cohort.
Methods: DNA was collected from 20 Follicular Lymphoma (FL) tumor samples, 20 Diffuse Large B-cell Lymphoma 
(DLBCL) tumor samples, neoplastic B-cells of 10 B-cell Chronic Lymphocytic Leukemia (B-CLL) patients and Buccal cell 
samples matched to 4 of these B-CLL patients. The cohort heterozygosity comparison method was developed and 
validated using LOH derived in a small cohort of B-CLL by traditional comparisons of tumor and normal DNA samples, 
and compared to the only alternative method for LOH analysis without patient matched controls. LOH candidate 
regions were then generated for enlarged cohorts of B-CLL, FL and DLBCL samples using our cohort heterozygosity 
comparison method in order to evaluate potential LOH candidate regions in these non-Hodgkin's lymphoma tumor 
subtypes.
Results: Using a small cohort of B-CLL samples with patient-matched normal DNA we have validated the utility of this 
method and shown that it displays more accuracy and sensitivity in detecting LOH candidate regions compared to the 
only alternative method, the Hidden Markov Model (HMM) method. Subsequently, using B-CLL, FL and DLBCL tumor 
samples we have utilised cohort heterozygosity comparisons to localise LOH candidate regions in these subtypes of 
non-Hodgkin's lymphoma. Detected LOH regions included both previously described regions of LOH as well as novel 
genomic candidate regions.
Conclusions: We have proven the efficacy of the use of cohort heterozygosity comparisons for genome-wide 
mapping of LOH and shown it to be in many ways superior to the HMM method. Additionally, the use of this method 
to analyse SNP microarray data from 3 common forms of non-Hodgkin's lymphoma yielded interesting tumor 
suppressor gene candidates, including the ETV3 gene that was highlighted in both B-CLL and FL.
Background
The elimination of tumor suppressor gene (TSG) func-
tion contributes to carcinogenesis and cancer progres-
sion. Early work on the RB1 gene locus suggested two hits
in TSGs were required to disrupt TSG function [1,2].
That is, both alleles of a TSG must be interrupted by
mutation or allelic loss in order to render it inactive. Loss
of heterozygosity (LOH), the transition from germ-line
heterozygosity at a polymorphic locus to somatic
homozygosity, is a hallmark of allelic loss and thus repre-
sents one of the two hits required for TSG inactivation.
Analysis of LOH is therefore important in cancer
research in order to localize potential TSGs that may
have a role in disease genesis and progression [3]. The
introduction of high-density single nucleotide polymor-
phism (SNP) arrays has allowed high-resolution mapping
of LOH and the delineation of minimally lost regions that
indicate the presence of important TSGs [4]. The conven-
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tional method for LOH analysis relies on the comparison
of SNP genotypes between tumor DNA samples and
patient-matched control (germ-line) DNA samples
obtained from normal (non-tumor) tissue. LOH deter-
mined in this manner will henceforth be referred to as
'conventional LOH'. The limitation of conventional meth-
ods of LOH analysis is that many archived tumor samples
are not accompanied by patient-matched control tissue
resulting in the under-utilization of these potentially
valuable resources for interrogation of LOH.
Analysis of allelic copy number, using Hidden Markov
Model (HMM)-based approaches such as QuantiSNP [5]
and PennCNV [6], allow detection of LOH resulting from
hemizygous deletion of single alleles, but lack the capac-
ity to detect copy-number neutral LOH. Recently, an
alternative method was described that utilizes a HMM to
infer the presence of LOH from SNP microarray data of
non-matched tumor samples by the absence of heterozy-
gosity [7], thus allowing detection of copy-number neu-
tral LOH. This method utilizes long strings of SNPs with
homozygous calls to infer LOH and generates high num-
bers of candidate regions spanning large genetic dis-
tances. In order to overcome this limitation and increase
the resolution of LOH mapping, we have developed a
method to infer the presence of LOH regions through the
comparison of SNP heterozygosity values between case
and reference cohorts (Cohort Heterozygosity Compari-
son; CHC). The CHC method infers LOH candidate
regions by the presence of short strings of SNPs which
exhibit consistently lower prevalence of heterozygosity in
the case cohort compared to the control cohort. The
method is based on the hypothesis that decreased
heterozygosity of closely spaced SNPs in the case cohort
compared to the control cohort indicates a region of
LOH. The CHC method calculates heterozygosity values
for SNPs covering the entire genome in case and control
cohorts, and then identifies and recovers the data from
informative SNPs. By directly comparing heterozygosity
of informative SNPs, groups of SNPs with significant dif-
ferences in heterozygosity between the cohorts can be
identified.
In this study, the CHC method was employed using
SNP data from Affymetrix 250 K SNP arrays to infer
LOH regions in tumor samples from B-cell Chronic Lym-
phocytic Leukemia (B-CLL), Diffuse Large B-cell Lym-
phoma (DLBCL) and Follicular Lymphoma (FL) patients.
SNP array data from patient-matched buccal samples
from four of the B-CLL patients was initially used to
definitively map LOH by conventional methods in order
to determine regions that will henceforth be referred to
as 'conventional LOH'. These 'conventional LOH' regions
were used in order to validate 'inferred LOH' regions gen-
erated by the CHC method. Validation of 'conventional
LOH' was additionally performed by high-density micro-
satellite analysis. This work, as well as direct comparison
of the efficacy of the CHC method with that of the only
alternative (HMM) method, highlighted the utility of
cohort heterozygosity comparisons for mapping LOH
candidate regions without the need for patient-matched
control samples. We therefore performed CHC analysis
on larger numbers of FL, DLBCL and B-CLL samples in
order to elucidate LOH candidate regions with potential
roles in disease pathogenesis.
Methods
Patient Samples and DNA Extraction
Peripheral blood samples were obtained from B-CLL
patients (n = 10) through the Prince Charles and Gold
Coast Hospitals. Lymphocytes were enriched from 3 mL
of whole-blood using ACCUSPIN™ system HIS-
TOPAQUE®-1077 columns (Sigma-Aldrich) according to
the manufacturer's protocol and B-cells were isolated
from lymphocyte enrichments using Dynabeads® CD19
(Invitrogen) and a magnetic particle concentrator accord-
ing to the manufacturer's protocol. Following isolation of
B-cells, the cells were lysed by the addition of 600 μL of
lysis buffer (Qiagen) and passing through a 20-guage nee-
dle. DNA was purified from lysed cells using QIAamp
DNA Tissue Mini Kits according to the manufacturer's
protocol. Buccal cell samples were collected from 6 of the
B-CLL patients using Catch-All sample collection swabs
(Epicentre Biotechnologies), and DNA isolated using
BuccalAmp DNA extraction kits (Epicentre Biotechnol-
ogy) according to the manufacturer's protocol.
FL (n = 20) and DLBCL (n = 20) tumor specimens were
obtained through the Australian Leukemia and Lym-
phoma Group (ALLG) Tissue Bank (Princess Alexandra
Hospital, Queensland, Australia) and BioOptions BioRe-
pository Service http://www.biooptions.com/. DNA was
extracted from tumor tissue using a modified column
extraction protocol. 10 mg of tissue was homogenized in
1 mL of phosphate-buffered saline (pH 7.4) using a rotor-
strator homogenizer. Protein was digested by incubation
with Proteinase-K at 70°C for 30 min. DNA was purified
from the milieu using QIAamp DNA Blood Midi Kit
(Qiagen) according to the manufacturers protocol and all
samples that were below a concentration of 100 ng/μL
were precipitated in ethanol and re-eluted in a smaller
volume.
Single Nucleotide Polymorphism Microarrays
DNA samples were amplified, fragmented, labelled and
hybridized to Affymetrix 250 K Sty SNP microarrays in
accordance with the manufacturer's protocol. Raw data
was extracted from image files using GeneChip Operat-
ing System software (GCOS; Affymetrix). SNP genotyp-
ing and HMM-based LOH analysis was performed using
GeneChip Genotyping Software (GTYPE; Affymetrix). ItGreen et al. BMC Cancer 2010, 10:195
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should be noted that the HMM-method does not utilize
comparison to any normal sample, and generates LOH
candidate regions based upon the genotypes generated
from the tumour samples only. 'Conventional LOH' was
d e t e c t e d  i n  4  B - C L L  p a t i e n t s  b y  c o m p a r i s o n  o f  S N P
microarray genotypes from Buccal and tumor samples.
This was performed using dChipSNP software as previ-
ously described [8].
Microsatellite Analysis of LOH
Case tumor and buccal DNA samples were amplified
using the Illustra Genomiphi V2 DNA amplification kit
(GE Healthcare) according to the manufacturer's proto-
col. Each sample was genotyped at the Australian
Genome Research Facility (AGRF, Sydney, Australia)
using a standardized set of 63 microsatellites markers for
chromosome 1. These markers span chromosome 1 with
an average resolution of 5 cM http://appliedbiosys-
tems.com/.
Evaluation and Statistical Analysis of 'Inferred LOH' Regions
In order to evaluate the 'Inferred LOH' regions generated
by CHC and HMM methods, annotation data from the
Affymetrix GeneChip®  Genotyping Software was ana-
lyzed in Microsoft Excel. Each inferred LOH region was
then plotted on the spreadsheet and evaluated for size
and distance from SNPs showing 'conventional LOH'.
Size was calculated using the physical position of the
SNPs at the end of each region. The distance from 'con-
ventional LOH' was calculated using the physical posi-
tions of the SNPs at the end of each region and the
physical position of the closest SNP showing 'conven-
tional LOH'. If candidate regions encompassed SNPs
showing 'conventional LOH', the distance to the closest
'conventional LOH' was determined to be 0.
Normality of the distribution of delta values was tested
using Blom's formula in order to ensure the correct
model was being employed for power analysis. To estab-
lish differences in sensitivity and specificity of the CHC
method with different contiguous point thresholds
(CPT), correlations between CPT and the percentage of
regions encompassing 'conventional LOH' or the distance
of regions from 'conventional LOH' were derived using
Pearsons correlation and the full data set for each CPT. In
order to illustrate the fact that the primary determining
factor for the distance of LOH regions inferred by CHC
from the 'conventional LOH' was the resolution of the
SNPs within the region, Pearsons correlation was used to
compare the distance from the closest SNP showing 'con-
ventional LOH' and the distance between SNPs. Only the
'inferred LOH' regions derived with a CPT of 5, and that
did not encompass markers showing 'conventional LOH'
(n = 159) were employed for this analysis. Demonstration
of the need for the CHC method to have high heterozy-
gosity frequencies at SNPs showing 'conventional LOH'
in order to map LOH candidate regions over them when
employing small cohort samples sizes was achieved by
comparison of heterozygosity frequencies of SNPs show-
ing 'conventional LOH' found inside candidate regions
compared to those adjacent to candidate regions. This
was achieved through the use of an independent-samples
Students T-test of all regions generated with a CPT of 5.
In order to highlight the utility of the enrichment score
(ES) generated from the sum of delta values, Pearsons
correlation was used to correlate the ES values of all
'inferred LOH' regions generated with a CPT of 5 with
the distance of each region from the closest SNP showing
'conventional LOH'. To evaluate the efficacy of the HMM
method, the percentage of HMM candidate regions that
encompassed SNPs showing 'conventional LOH' was
compared between patients by one-way ANOVA with
Bonferroni post-hoc analysis.
Cohort Heterozygosity Comparison Analysis of B-CLL, FL 
and DLBCL Samples
SNP microarray data for DLBCL, FL and B-CLL samples
was analysed using the CHC method with reference to
data generated from Caucasian HapMap samples. This
data is freely available from http://www.affymetrix.com.
It should be noted that different control samples were
used for each NHL disease sub-category in order to avoid
biasing the results. In order to ensure accuracy of LOH
regions, CHC analysis was performed using a delta
threshold of 0.4 and a CPT of 5. Regions of 'inferred LOH'
were ranked by enrichment score and the top 2 regions
for each subtype discussed.
Implementation
Selection of Informative Markers
Selection of informative SNPs (SNPi) is the first impor-
tant aspect of the CHC method. As heterozygous geno-
types are required to infer LOH using both the
conventional and CHC methods of analysis, it is impor-
tant that there be a likelihood of obtaining heterozygous
genotypes within a case cohort. In order to perform
cohort comparisons only those markers that were pre-
dicted to give a heterozygous call within the cohort were
deemed to be informative; that is, only those markers
with a population heterozygosity value (HV) greater than
or equal to the reciprocal of the cohort size. HV for the
given ethnicity is as determined by the SNP microarray
annotation data. In the initial validation set of four sam-
ples in this investigation, 55% of the SNPs on the array
were selected as informative markers; this translates to
>125,000 SNPs. But by increasing the sample size in the
secondary test sets of B-CLL, FL and DLBCL samples,
larger numbers of the SNPs were selected as informative.
Thus, the resolution of this method remains high even
with low sample sizes, but is improved with increasingGreen et al. BMC Cancer 2010, 10:195
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sample size due to inclusion of SNPs with lower heterozy-
gosity frequencies.
Calculation of Delta Values
Because of the potential to skew case and control
heterozygosity values, all markers with absent genotype
calls in any of the samples are removed from the analysis.
Heterozygosity values are then calculated for all remain-
ing SNPs for each cohort. A delta value (Δ), representa-
tive of the difference in heterozygosity value between
each cohort, is then calculated for each SNP.
Calculation of Delta Threshold
Different cohort sample sizes between investigations also
make it important to calculate the delta threshold for
each application of the CHC method. The statistical
power of different investigations is dependant upon their
respective sample sizes. With increasing sample size, a
lesser effect size (Δ) is needed in order to obtain statisti-
cally significant results, whilst maintaining the desired
minimum power (80%). The delta threshold is therefore
set to maintain a statistical power of 80% (α = 0.05). For
example, with the initial validation cohort (n = 4, σ = 0.3)
the delta threshold was calculated to be 0.5, whereas by
increasing the sample size to 10 in the secondary cohort
of B-CLL samples while maintaining the same standard
deviation the maximum required delta threshold
required to obtain 80% power was lowered to 0.3. This
means that with a sample size of 4 a 50% decrease in case
cohort heterozygosity frequency must be observed in the
case cohort compared to the reference cohort in order for
the marker to be deemed informative, whereas with a
sample size of 10 only a 30% decrease in case cohort
heterozygosity frequency is required for a marker to be
deemed informative. Increasing the cohort sample size
when using the CHC method of LOH analysis is therefore
expected to increase the specificity of the method and
hence decrease the number of type I errors. Statistical
power analysis was employed to calculate the delta value
required (i.e. effect size) to achieve a minimum power of
80% with the specified cohort sample size (α = 0.05). The
following formula was utilized to calculate the delta
threshold (ΔT), which was used to determine which delta
values were suggestive of LOH (ΔS). Within this formula,
σ represents the standard deviation, Z represents the Z-
score for a given value, a represents the level of signifi-
cance (set to 0.05), β represents type II error rate and n
represents the sample size.
Contiguous Point Threshold and Inferring LOH
The number of contiguous SNPs required to infer LOH
within a region is referred to as the contiguous point
threshold (CPT). Strings of contiguous SNPs larger than
or equal to the CPT and yielding informative delta values
are highlighted as 'inferred LOH' regions. By altering this
threshold users are able to modify the sensitivity and
specificity of the CHC method. Using a low CPT a com-
paratively higher number of 'inferred LOH' regions can
be localized compared to using a high CPT. However, this
increased sensitivity is accompanied by decreased speci-
ficity. Setting the CPT is therefore a trade-off between
sensitivity and specificity, and should be considered for
each application of this method. However, it is recom-
mended that a minimum CPT of 5 be employed in order
to ensure sufficient specificity.
Enrichment Score
In order to predict the proximity of 'inferred LOH'
regions to markers showing 'conventional LOH', an
enrichment score can be generated by summing the delta
values generated within an 'inferred LOH' region. This
enrichment score negatively correlates with the distance
to closest 'conventional LOH' marker, indicating that the
higher the enrichment score the closer the 'inferred LOH'
regions will link to markers showing 'conventional LOH'.
It is therefore recommended that the sequence immedi-
ately flanking CHC candidate regions with low enrich-
ment scores also be considered when searching for
candidate TSGs.
Automated Analysis using Cohort Heterozygosity 
Comparison
A platform for automated CHC analysis (Additional file
1), instructions for use (Additional file 2), and the case
and control input files (Additional files 3 and 4) utilized
for analysis B-CLL, FL and DLBCL cohorts in this manu-
script are available from the journal web-site.
Results
Validation of the Cohort Heterozygosity Comparison 
Method
Delta values were calculated for each informative SNP as
described above. These values demonstrated a positively
skewed normal distribution, as would be anticipated with
decreased heterozygosity frequency in the case cohort.
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Calculation of the delta threshold is an important facet of
the CHC method. With increasing cohort sample size a
decrease in the effect size (Δ) is required to obtain signifi-
cant results, whilst maintaining 80% power. For the initial
validation set of B-CLL samples (n = 4, σ = 0.3) the delta
threshold was calculated to be 0.5, for the subsequent test
set (n = 10, σ = 0.3) the delta threshold was calculated to
be 0.3.
The number of inferred regions for each CPT can be
seen in Table 1. From this it can be seen that increasing
the CPT decreased the number of LOH candidate regions
generated via the CHC method. A significant positive
correlation was found between CPT and the percentage
of regions that spanned SNPs showing 'conventional
LOH' (Pearsons correlation coefficient = 0.998; p =
0.002), and a significant negative correlation was found
between CPT and the mean distance of 'inferred LOH'
regions from the closest SNP showing 'conventional
LOH' (Pearsons correlation coefficient = -0.996; p =
0.004). It is therefore predicted that raising the CPT
increases the selectivity of the CHC method (i.e. decrease
the chance of a Type I error), but in return may also
decrease its sensitivity (i.e. increase the chance of a type
II error).
A striking trend was also observed whereby those
regions that did not encompass SNPs showing 'conven-
tional LOH' mapped directly adjacent to them. When
evaluating the LOH regions inferred with a CPT of 5,
those SNPs showing 'conventional LOH' that mapped
directly adjacent to regions of 'inferred LOH' were found
to have a mean heterozygosity of 0.19 (n = 159). The
mean population heterozygosity of SNPs showing 'con-
ventional LOH' that mapped inside 'inferred LOH'
regions was found to be 0.32 (n = 140), and was signifi-
cantly higher than those mapping adjacent to candidate
regions (p < 0.001). A positive correlation was found
between the distance of candidate regions from the clos-
est SNP showing 'conventional LOH' and the distance
between SNPs (Pearsons correlation coefficient = 0.290; p
= 0.022). A significant negative correlation was found
between enrichment score and the distance to the closest
SNP showing 'conventional LOH' (Pearsons correlation
coefficient = -0.143; p < 0.001).
Evaluation of the Hidden Markov Model Method
The HMM method for inferred LOH regions, associated
with the Affymetrix GeneChip®  Genotyping Software
CNAT 4.0 tool, generates scores of either 1 or 0 relating
to 'inferred LOH' or retention of heterozygosity respec-
tively. Regions with scores of 1 were classified as 'inferred
LOH' regions and are summarized in Table 2. This
method was found to generate large numbers of regions
that spanned large genomic distances and that had a vari-
able rate of success in encompassing 'conventional LOH'
in the CLL patients. In total for the four cases, 699
regions were selected as regions of 'inferred LOH' by the
HMM method. Of these, 82 regions overlapped in two
patients, 22 candidate regions overlapped in three
patients, and 2 candidate regions overlapped in all four
patients, resulting in 567 independent regions of 'inferred
LOH' for follow-up analysis from four cases. A significant
difference in the percentage of HMM candidate regions
encompassing SNPs showing 'conventional LOH' was
also noted between cases (p = 0.01). No feature of indi-
vidual case data was found to predict the percentage of
regions encompassing SNPs showing 'conventional LOH'.
Cohort Heterozygosity Comparison Analysis of NHL 
Subtypes
After validation of the CHC method, SNP array data for
DLBCL, FL and B-CLL samples was analysed using the
CHC method. This generated 9 LOH candidate regions
in DLBCL with enrichment scores ranging from 2.1 to
5.45, 10 LOH candidate regions in FL with enrichment
scores ranging between 2.2 and 4.65, and 65 candidate
regions in B-CLL with enrichment scores ranging from 2
to 5.8. The top two candidates for each NHL subtype, as
assessed by enrichment score, are displayed on Table 3.
Figure 1 shows a moving window analysis of the delta
scores over the 1q32.1 candidate locus for all 3 of the
NHL subtypes, showing its implication in CLL and FL but
not DLBCL. The 1q32.1 region highlighted by the CHC
method in CLL and FL cohorts, and the 3p25.3 region
highlighted in the CLL cohort, was not detected by the
H M M  m e t h o d  i n  a n y  o f  t h e s e  s a m p l e s .  H o w e v e r ,  t h e
HMM method did infer LOH over areas exceeding 500
Mbp in two FL samples that overlapped the compara-
Table 1: Validation of 'Inferred LOH' Regions Generated by the CHC Method
CPT No. of Regions Mean Region Size 
(bp)
Regions within 100 
kb of LOH*
Mean Distance from 
LOH* (bp)
3 1,263 67,145 89% 36,460
4 594 101,166 92% 30,582
5 299 119,886 93% 25,220
6 162 112,431 96% 21,316
*'Conventional LOH'Green et al. BMC Cancer 2010, 10:195
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tively smaller 5q11.2 candidate region highlighted by the
CHC method. The HMM method also inferred LOH over
a 965 Kbp in one DLBCL sample that overlapped the
smaller 4q32.2 candidate region highlighted by the CHC
method. Interestingly, the most notable overlap in candi-
date prediction between the HMM and CHC methods
occurred at the 3q11.2 candidate region, in which the
HMM region inferred LOH in 7 DLBCL samples with
sizes ranging from 681 Kbp up to all of chromosome 3.
Discussion
We have developed a method for inferring regions of
LOH by analyzing cohort heterozygosity values using
SNP arrays, without the need for patient-matched sam-
ples. Initially, LOH regions were inferred in a small
cohort of B-CLL patients using the Cohort Heterozygos-
ity Comparison method. In order to investigate the effi-
cacy of this method, regions of 'conventional LOH' were
mapped in these patients through the use of SNP array
data from patient-matched buccal samples, which was
further validated by analysis of microsatellite markers.
Following validation of this novel method of LOH analy-
sis, CHC analysis was used to infer LOH in an extended
cohort of B-CLL samples as well as larger cohorts of FL
and DLBCL samples.
The CHC method employs genotype data generated by
SNP microarray in order to detect regions of decreased
heterozygosity frequency in the case cohort compared to
the control cohort. Due to the decreasing heterozygosity
of markers of markers on modern SNP array platforms,
the CHC method only utilizes markers with a predicted
capacity to generate at least one heterozygous genotype
within each of the case and control cohorts. For each of
these SNPs, delta values are calculated that correspond to
the difference in heterozygosity between cases and con-
trols. Decreases in heterozygosity frequency, as demon-
s t r a t e d  b y  a  p o s i t i v e  d e l t a  s c o r e ,  a r e  c o n s i d e r e d  t o  b e
suggestive of LOH if they exceed a set threshold. This
threshold (ΔT) is one of the modulatory parameters of the
CHC method that can be used to alter the balance
Table 2: Validation of 'Inferred LOH Regions Generated by the HMM Method
Sample No. of Regions Mean Region Size 
(bp)
Regions within 100 
kb of LOH
Mean Distance from 
LOH (bp)
1 185 1,123,018 91% 33,850
2 187 1,003,721 78% 154,242
3 121 847,306 62% 230,310
4 206 892,220 97% 5,189
Total 699 975,359 82% 91,619
*'Conventional LOH'
Figure 1 Rolling window representation of delta values across the 1q23.1 cytoband for CLL, FL and DLBCL cohorts. The position of each SNP 
over this region is shown by a black vertical bar. It can be seen that high delta values are obtained for contiguous SNPs over the ETV3 gene locus, 
marked with a red box, in CLL and FL cohorts but not in the DLBCL cohort.
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between sensitivity and specificity, but is usually set to
maintain sufficient statistical power for the analysis. The
second modulatory parameter contiguous point thresh-
old (CPT), which is used to highlight regions as inferring
LOH only if the number of contiguous markers exceeding
ΔT is equal to or above the CPT. The CPT is applied in
order to minimize false positives, and the ability of this
parameter to modulate the sensitivity and specificity of
this method is aptly shown by the decreasing number of
inferred LOH regions and more accurate inference of
LOH with increasing CPT, respectively (Table 1).
A caveat of the CHC method when employing small
sample sizes is the increased requirement for high
heterozygosity frequencies in order to detect LOH. This
lead to a portion of the regions within the validation
cohort mapping adjacent to, rather than encompassing,
SNPs showing 'conventional LOH'. In this investigation
the validation cohort sample size was modest; meaning
that the effect size must be large in order to define
regions with significantly decreased heterozygosity in the
case cohort compared to the control cohort. In the vali-
dation cohort of 4 samples, when employing a CPT of 5
and a delta threshold of 0.5, there must be 5 consecutive
SNPs with a 50% decrease in heterozygosity between the
case and control cohorts in order LOH to be inferred.
This means the CHC method can only detect LOH in
small sample sizes if the region of LOH has a high enough
initial rate of heterozygosity. In instances in which SNPs
showing 'conventional LOH' had low population
heterozygosity, the 'inferred LOH' region frequently
m a p p e d  d i r e c t l y  a d j a c e n t  t o  t h e m  r a t h e r  t h a n  e n c o m -
passing them. This is supported by the fact that the SNPs
showing 'conventional LOH' that mapped adjacent to
regions of 'inferred LOH' derived by the CHC method
had a significantly lower population heterozygosity than
those that mapped inside the 'inferred LOH' regions. Fur-
thermore, the distance of these adjacently positioned
regions of 'inferred LOH' from 'conventional LOH' was
determined primarily by the resolution of markers within
each respective genomic region. The need for high popu-
lation heterozygosity frequencies in order to map SNPs
showing 'conventional LOH' within regions of 'inferred
LOH' generated by the CHC method can be alleviated by
increasing the cohort sample size. This would augment
the power of the investigation and decrease the effect size
required to define SNPs as being suggestive of LOH.
However, even with the small sample size in the valida-
tion cohort the CHC method was shown to successfully
infer LOH regions closely to SNPs showing 'conventional
LOH', including those with low population heterozygosi-
ties. Furthermore, utilization of the CHC method with
small sample sizes is further aided by the use of enrich-
ment scores for each 'inferred LOH' region. This score is
a sum of the heterozygosity frequency delta values, and
was shown to significantly and negatively correlate with
the distance of 'inferred LOH' from 'conventional LOH'.
The only current alternative to the CHC method for
high resolution mapping of LOH using SNP microarray
data without the need for patient-matched control sam-
ples is a method based on an HMM algorithm [7]. This
method relies on identification of long strings of homozy-
gous SNP genotypes in order to infer LOH. The HMM
method therefore primarily differs from the CHC algo-
rithm due to its mode of analysis being directed linearly
within a single sample, while the CHC algorithm applies
cross-sectional interrogation of genomic regions across
entire cohorts of samples. This means that, while the
HMM algorithm is predisposed to generating false-posi-
tive LOH calls as a result of consanguinity in individual
patient's family trees and the subsequent enrichment of
homozygosity, the cross-sectional approach adopted by
the CHC algorithm is not as heavily affected by individual
genetic background. We employed this method to ana-
lyze each of the four initial validation case samples in this
investigation. It yielded 699 candidate regions with an
average size of over 95 kb between the four cases. Only
19% of these candidate regions overlapped in two or more
patients, resulting in 567 independent genomic regions
that were suggestive of LOH. The HMM method does
Table 3: Top 2 Regions of 'Inferred LOH' for each NHL Subtype
Disease Location Start Position Finish Position ES Candidate
CLL 1q23.1 155269409 155393832 5.80 ETV3
CLL 3p25.3 9972054 10143892 5.80 FANCD2
FL 5q11.2 56022313 67005198 4.65 ERCC8
FL 1q23.1 155269409 155320805 3.55 ETV3
DLBCL 3q11.2 96553777 96717069 5.45 -
DLBCL 4q32.3 165412095 165440501 4.30 ANP32C
Top 'inferred LOH' regions, as determined by enrichment score, showing the cytogenetic location, start position and finish position 
determined by the location of first and last SNPs, and the candidate gene determined by annotation data.Green et al. BMC Cancer 2010, 10:195
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not provide a cumulative index or probability of LOH
across all samples, and thus differences between this
method and the CHC method are to be expected. How-
ever, when comparing the accuracy of the HMM-gener-
ated regions to the regions inferred by the CHC method
with the recommended CPT, it can be seen that the CHC
method delineated regions that were on average over 70%
smaller, and more frequently mapped within the immedi-
ate vicinity of 'conventional LOH'. It should be noted that,
although the size of HMM-inferred regions of LOH could
be decreased by altering the state change parameter, this
would also further decrease the specificity of the method.
Nonetheless, the CHC method was found to infer LOH
more specifically and within smaller genomic regions
than the HMM method. This suggests that, not only is
the CHC method more accurate in inferring LOH, but
the increased precision may allow more specific delinea-
tion of smaller regions of LOH. Although there are clear
advantages in combining cases into a cohort as part of the
CHC method, this approach inhibits the ability to infer
LOH regions within individual samples. Instead, the
CHC method is more appropriately employed in generat-
ing candidate LOH regions implicating genes with a
broad role in disease pathogenesis rather than a variable
importance on a case-to-case basis.
In order to investigate whether automated analysis of
larger samples of NHL patients could derive hypotheti-
cally important candidates, the CHC method was used to
analyze larger cohorts B-CLL, FL and DLBCL samples.
Using the enrichment score, the top two LOH candidate
regions for each disease subtype were investigated for
candidate genes that may possess a hypothetical tumor-
suppressor function in NHL. Although one of the regions
of 'inferred LOH' in DLBCL mapped over a genetic
region with no closely linked coding loci, this region
(3q11.2) has been shown to be lost in a range of cancers
including acute lymphoblastic leukemia and mantle cell
lymphoma [9,10], and the remaining 5 candidate regions
were closely linked to attractive TSG candidates. Among
these were two DNA repair genes (FANCD2, ERCC8), an
inhibitor of RAS-mediated transformation (ANP32C),
and a repressor of NFκB activity that was highlighted in
both B-CLL and FL cohorts (ETV3).
The association between DNA repair genes and the
pathogenesis of NHL is demonstrated by lymphoma pre-
disposition within immunodeficiency cases containing
mutations in genes mediating DNA damage repair [11] to
developing NHL, as well as the numerous associations
between polymorphisms in DNA repair genes and
genetic susceptibility to NHL [12-14]. It is therefore not
surprising that DNA repair genes may play a central
tumor suppressor role in NHL. The FANCD2 gene was
linked with a region of 'inferred LOH' highlighted in the
B-CLL patient cohort, and functions in by forming com-
plexes with BRCA1 or RAD51 and mediating repair of
transcriptionally active genes [15]. Furthermore, this
gene has also been shown to be essential for maintaining
the G2 cell-cycle checkpoint [16]. The ERCC8 gene is also
involved in DNA repair of transcriptionally active genes
[17], and was linked with a region of inferred LOH in the
FL patient cohort. Further support for this gene as a
potential TSG is provided by the increased frequency of
cancer in Cackayne's syndrome patients in which the
ERCC8 gene is mutated [18]. The targeting of the
FANCD2 and ERCC8 genes by LOH, as inferred by the
CHC method, indicates that knock-out of their function
may allow for the accumulation of mutations within tran-
scriptionally active genes. Furthermore this may also be
compounded by subsequent un-checked progression
through the G2 checkpoint without FANCD2-associated
cell-cycle arrest or apoptotic induction.
The ANP32C gene was highlighted as a potential TSG
by CHC analysis of the DLBCL patient cohort. This gene
has been previously described as a tumor suppressor
gene, and elucidation of its function revealed that this
role may be due to repression of RAS-mediated tumori-
genesis [18]. However, our implication of this gene in the
pathogenesis of NHL is a completely novel finding. The
most interesting finding within the CHC analysis results
was the revelation of ETV3 as a potential TSG in both B-
CLL and FL patient cohorts. This gene is part of the ETS-
family of tumor suppressors and functions in repression
of NFκB-activated transcription [19]. LOH of the ETV3
locus at 1q23.1 has been previously demonstrated in B-
CLL [20], and its potential as a TSG is supported by the
importance of NFκB signaling in promoting proliferation
and inhibiting apoptosis within lymphocytes [21]. The
implication of genes with well defined tumor suppressor
roles by cohort heterozygosity comparison of B-CLL, FL
and DLBCL provides evidence that this novel method of
analysis infers LOH within plausible TSGs. Although the
implication of these candidate genes is only a preliminary
finding, and validation by microsatellite analysis in a
larger cohort of samples would be required in order to
definitively link them with the pathogenesis of NHL, they
clearly illustrate the utility of the CHC method for deriva-
tion of LOH candidates.
Conclusions
We have developed a method of LOH analysis using case
and unmatched control samples that differs from that
which is currently available by directing the analysis
cross-sectionally across multiple genomes within a
cohort. Analysis of SNP array data with the CHC method
was shown to infer LOH regions that linked closely to
SNPs showing 'conventional LOH'. This method can be
adopted for investigation of varied sample sizes, and the
specificity and sensitivity of the method can be tailored toGreen et al. BMC Cancer 2010, 10:195
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suit the objectives of each investigation. The candidate
regions generated by the CHC method were considerably
smaller and mapped significantly closer to SNPs showing
'conventional LOH' than the candidate regions generated
by it's only current alternative, the HMM method. The
utility of this method was further highlighted by its use to
elucidate hypothetical, but potentially important, regions
of LOH in three subtypes of NHL, including the ETV3
gene that was highlighted in both B-CLL and FL patient
cohorts.
Additional material
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